[en] OBJECTIVES: Strontium ranelate 2 g/day has proven efficacy against vertebral and nonvertebral fracture over 5 years in postmenopausal osteoporosis, though many women require longer-term treatment. This article describes the efficacy, safety, and tolerability of this agent over 8 years. METHODS: Postmenopausal osteoporotic women having participated in the 5-year efficacy trials SOTI and TROPOS were invited to enter a 3-year open-label extension study. The results presented here focus on patients who received strontium ranelate for 8 years. RESULTS: At the extension baseline, the population treated for 8 years (n=879; 79.1+/-5.6 years) had femoral neck T-score of -2.61+/-0.71. The cumulative incidences of new vertebral and nonvertebral fractures (13.7% and 12.0%, respectively) over years 6 to 8 were non-statistically different from the cumulative incidences in the first 3 years of the original studies (11.5% and 9.6%). Lumbar spine, femoral neck, and total hip bone mineral density (BMD) increased throughout the 8-year period. Annual relative change in BMD was significant at every visit, except the 8-year visit for femoral neck and total hip BMD. Strontium ranelate was safe and well tolerated over 8 years. CONCLUSIONS: Long-term treatment with strontium ranelate 2 g/day in postmenopausal osteoporotic women leads to continued increases in BMD at all sites. The data also provide some evidence for a sustained antifracture efficacy.
Disciplines :
Médecine générale & interne
Auteur, co-auteur :
Reginster, Jean-Yves ; Université de Liège - ULiège > Département des sciences de la santé publique > Epidémiologie et santé publique
Bruyère, Olivier ; Université de Liège - ULiège > Département des sciences de la santé publique > Epidémiologie et santé publique - Département des sciences de la santé publique
Sawicki, A.
Roces-Varela, A.
Fardellone, Patrice
Roberts, A.
Devogelaer, Jean-Pierre
Langue du document :
Anglais
Titre :
Long-term treatment of postmenopausal osteoporosis with strontium ranelate: Results at 8 years.
Briot K., Tremollieres F., Thomas T., et al. How long should patients take medications for postmenopausal osteoporosis?. Joint Bone Spine 74 (2007) 24-31
Mellstrom D.D., Sorensen O.H., Goemaere S., et al. Seven years of treatment with risedronate in women with postmenopausal osteoporosis. Calcif. Tissue Int. 75 (2004) 462-468
Bone H.G., Hosking D., Devogelaer J.P., et al. Ten years' experience with alendronate for osteoporosis in postmenopausal women. N. Engl. J. Med. 350 (2004) 1189-1199
Siris E.S., Harris S.T., Eastell R., et al. Skeletal effects of raloxifene after 8 years: results from the continuing outcomes relevant to Evista (CORE) study. J. Bone Miner. Res. 20 (2005) 1514-1524
Black D.M., Schwartz A.V., Ensrud K.E., et al. Effects of continuing or stopping alendronate after 5 years of treatment The Fracture Intervention Trial Long-term Extension (FLEX): a randomized trial. JAMA 296 (2006) 2927-2938
Brennan T.C., Rybchyn M.S., Conigrave A.D., and Mason R.S. SU375: strontium promotes human osteoblast replication and decreases their osteoclastogenic abilities in primary human osteoblasts. J. Bone Miner. Res. 21 (2006) S301
Brennan T.C., Rybchyn M.S., Halbout P., Conigrave A.D., and Mason R.S. P132-T: strontium ranelate effects in human osteoblasts support its uncoupling effect on bone formation and bone resorption. Calcif. Tissue Int. 80 (2007) S72-S73
Baron R., and Tsouderos Y. In vitro effects of S12911-2 on osteoclast function and bone marrow macrophage differenciation. Eur. J. Pharmacol. 450 (2002) 11-17
Marie P.J., Ammann P., Boivin G., et al. Mechanisms of action and therapeutic potential of strontium in bone. Calcif. Tissue Int. 69 (2001) 121-129
Marie P.J. Strontium ranelate: new insights into its dual mode of action. Bone 40 (2007) S5-S8
Ammann P., Shen V., Robin B., et al. Strontium ranelate improves bone resistance by increasing bone mass and improving architecture in intact female rats. J. Bone Miner. Res. 19 (2004) 2012-2020
Arlot M.E., Jiang Y., Genant H.K., et al. Histomorphometric and mu-CT analysis of bone biopsies from postmenopausal osteoporotic women treated with strontium ranelate. J. Bone Miner. Res. 23 (2008) 215-222
Meunier P.J., Roux C., Seeman E., et al. The effects of strontium ranelate on the risk of vertebral fracture in women with postmenopausal osteoporosis. N. Engl. J. Med. 350 (2004) 459-468
Reginster J.Y., Seeman E., De Vernejoul M.C., et al. Strontium ranelate reduces the risk of nonvertebral fractures in postmenopausal women with osteoporosis: Treatment of Peripheral Osteoporosis (TROPOS) study. J. Clin. Endocrinol. Metab. 90 (2005) 2816-2822
Reginster J.Y., Felsenberg D., Boonen S., et al. OC49: strontium ranelate demonstrates efficacy against hip fracture over 3 and 5 years in postmenopausal women at high risk of hip fracture. Osteoporos. Int. 19 (2008) S26-S27
Reginster J.-Y., Felsenberg D., Boonen S., et al. Effects of long-term strontium ranelate treatment on the risk of non-vertebral and vertebral fractures in postmenopausal osteoporosis: results of a 5-year, randomized, placebo-controlled trial. Arthritis Rheum. 58 (2008) 1687-1695
Meunier P.J., and Reginster J.Y. Design and methodology of the phase 3 trials for the clinical development of strontium ranelate in the treatment of women with postmenopausal osteoporosis. Osteoporos. Int. 14 Suppl. 3 (2003) S66-S76
Roux C., Reginster J.-Y., Fechtenbaum J., et al. Vertebral fracture risk reduction with strontium ranelate in women with postmenopausal osteoporosis is independent of baseline risk factors. J. Bone Miner. Res. 21 (2006) 536-542
Genant H.K., Wu C.Y., Van Kuijk C., et al. Vertebral fracture assessment using a semiquantitative technique. J. Bone Miner. Res. 8 (1993) 1137-1148
Slosman D.O., Provvedini D.M., Meunier P.J., et al. The use of different dual X-ray absorptiometry brands in a multicenter clinical trial. Consequences and limits. J. Clin. Densitom. 2 (1999) 37-44
Siris E.S., Brenneman S.K., Barrett-Connor E., et al. The effect of age and bone mineral density on the absolute, excess, and relative risk of fracture in postmenopausal women aged 50-99: results from the National Osteoporosis Risk Assessment (NORA). Osteoporos. Int. 17 (2006) 565-574
Finigan J., Greenfield D.M., Blumsohn A., et al. Risk factors for vertebral and nonvertebral fracture over 10 years: a population-based study in women. J. Bone Miner. Res. 23 (2008) 75-85
Kanis J.A., Johnell O., Oden A., et al. Ten year probabilities of osteoporotic fractures according to BMD and diagnostic thresholds. Osteoporos. Int. 12 (2001) 989-995
Cauley J.A., Hochberg M.C., Lui L.Y., et al. Long-term risk of incident vertebral fractures. JAMA 298 (2007) 2761-2767
Kanis J.A., Burlet N., Cooper C., et al. European guidance for the diagnosis and management of osteoporosis in postmenopausal women. Osteoporos. Int. 19 (2008) 399-428
Boivin et al. In osteoporotic women treated with strontium ranelate, stontium is located in bone formed during treatment with a maintained degree of mineralisation. Ostoporosis international. 2009 Jul 14.
Bruyere O., Roux C., Detilleux J., et al. Relationship between bone mineral density changes and fracture risk reduction in patients treated with strontium ranelate. J. Clin. Endocrinol. Metab. 92 (2007) 3076-3081
Colon-Emeric C.S. Ten vs five years of bisphosphonate treatment for postmenopausal osteoporosis: enough of a good thing. JAMA 296 (2006) 2968-2969
Reginster J.Y., Minne H.W., Sorensen O.H., et al. Randomized trial of the effects of risedronate on vertebral fractures in women with established postmenopausal osteoporosis. Osteoporos. Int. 11 (2000) 83-91
Harris S.T., Watts N.B., Genant H.K., et al. Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis. JAMA 282 (1999) 1344-1352
Compston J.E., and Seeman E. Compliance with osteoporosis therapy is the weakest link. Lancet 368 (2006) 973-974
